Drug Trial Radar · NCT02297438
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
340
Actual
Start
Mar 23, 2015
Primary completion
Aug 31, 2020
Study completion Feb 24, 2025
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 21, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is designed to compare the clinical benefit following treatment with letrozole in combination with Palbociclib versus letrozole in combination with placebo in Asian postmenopausal women with ER(+)/HER2(-) advanced breast cancer who have not received prior systemic anti cancer therapies for their advanced/metastatic disease.
Conditions
- Breast Neoplasms
Interventions
PalbociclibDrug
Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
LetrozoleDrug
Letrozole, 2.5mg, orally once daily (continuously)
PlaceboDrug
Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
LetrozoleDrug
Letrozole, 2.5mg, orally once daily (continuously)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion DateTime frame: Randomization up to 65 months
Locations
54 sites in 5 countries. Site status is shown where the registry gives one.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, China
307 Hospital of PLA
Beijing, China
Beijing Cancer Hospital
Beijing, China
Peking University Third Hospital/Department of Oncology
Beijing, China
Chinese PLA General Hospital/Oncology
Beijing, China
Oncology Department, the Second Affiliated Hospital of Third Military Medical University, PLA
Chongqing, China
Fudan University Shanghai Cancer Center
Shanghai, China
The First Affiliated Hospital of Bengbu Medical College/Medical Oncology Department
Bengbu, Anhui, China
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Fujian Medical University Union Hospital/Medical Oncology Department
Fuzhou, Fujian, China
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China
Zhongshan Ophthalmic Center,Sun Yat-Sen University
Guangzhou, Guangdong, China
Breast Tumor Center, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Harbin Medical University Cancer Hospital/Oncology Department
Harbin, Heilongjiang, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Hubei Cancer Hospital
Wuhan, Hubei, China
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
Hunan Provincial Tumor Hospital/Breast Internal Medicine Department
Changsha, Hunan, China
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China
Jiangsu Province Hospital
Nanjing, Jiangsu, China
The First Hospital of Jilin University
Changchun, Jilin, China
Jilin Provincial Cancer Hospital
Changchun, Jilin, China
The First Hospital of China Medical University/Oncology Department
Shenyang, Liaoning, China
Liaoning Province Cancer Hospital
Shenyang, Liaoning, China
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Tianjin Cancer Hospital/Breast cancer department
Tianjin, Tianjin Municipality, China
The Tumor Hospital of Yunnan Province
Kunming, Yunnan, China
The First Affiliated Hospital of College of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Sir Run Run Shaw Hospital of College of Medicine of Zhejiang University, Center for Oncology
Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Department of Clinical Oncology
Hong Kong, Hong Kong
Queen Mary Hospital
Hong Kong, Hong Kong
Raffles Cancer Centre
Singapore, Singapore
Parkway Cancer Centre
Singapore, Singapore
Tan Tock Seng Hospital
Singapore, Singapore
Tan Tock Seng Hospital
Singapore, Singapore
China Medical University Hospital
Taichung, Taiwan
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.